Apalutamid for treatment of nonmetastatic castration-resistant prostste cancer – case study Case report

Article Sidebar

PDF PDF (Język Polski)


Published: Mar 31, 2023
DOI: https://doi.org/10.24292/01.OR.131319323
Keywords:
non-metastatic castration-resistant prostate cancer, nmCRPC, androgen receptor targeted agents, ARTA, apalutamide, darolutamide, enzalutamide

Main Article Content

Bożena Sikora-Kupis
Department of Urogenital Cancer, The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw

Abstract

A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration- resistant prostate cancer who was treated with apalutamide.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Sikora-Kupis B. Apalutamid for treatment of nonmetastatic castration-resistant prostste cancer – case study. OncoReview [Internet]. 2023Mar.31 [cited 2024Nov.22];13(1(49):6-. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/2786
Issue
Vol 13 No 1(49) (2023)
Section
SUPPORTIVE CARE IN ONCOLOGY

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021; 519: 20-9. http://doi.org/10.1016/j.canlet.2021.06.010.
2. Cattrini C, Caffo O, De Giorgi U et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nm- CRPC): A Critical Review. Cancers (Basel). 2022; 14(7): 1792.
3. Mateo J, Fizazi K, Gillessen S et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019; 75(2): 285-93.
4. Roumiguié M, Paoletti X, Neuzillet Y et al. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. Future Oncol. 2021; 17(14): 1811-23.
5. Mori K, Mostafaei H, Pradere B et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020; 25: 1892-900.